E13.52

Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene

Risk-adjusting (HCC)Billable code

HCC risk adjustment mapping

CMS-HCC V28

HCC37

Diabetes with Chronic Complications

HCC263

Atherosclerosis of Arteries of the Extremities with Ulceration or Gangrene

CMS-HCC ESRD V24

HCC18

Diabetes with Chronic Complications

HCC106

Atherosclerosis of the Extremities with Ulceration or Gangrene

RxHCC V08

RXHCC30

Diabetes with Complications

Coding notes

Excludes 1 never coded together · Excludes 2 may co-exist

This code · E13.52
Synonyms

Other specified diabetes mellitus with diabetic gangrene

Inherited from E13Other specified diabetes mellitus
Includes

diabetes mellitus due to genetic defects of beta-cell function diabetes mellitus due to genetic defects in insulin action postpancreatectomy diabetes mellitus postprocedural diabetes mellitus secondary diabetes mellitus NEC

Excludes 1

diabetes (mellitus) due to autoimmune process (E10.-) diabetes (mellitus) due to immune mediated pancreatic islet beta-cell destruction (E10.-) diabetes mellitus due to underlying condition (E08.-) drug or chemical induced diabetes mellitus (E09.-) gestational diabetes (O24.4-) neonatal diabetes mellitus (P70.2) type 1 diabetes mellitus (E10.-)

Use additional

code to identify control using: injectable non-insulin antidiabetic drugs (Z79.85) insulin (Z79.4) oral antidiabetic drugs (Z79.84) oral hypoglycemic drugs (Z79.84)

Inherited from chapter 4Endocrine, nutritional and metabolic diseases
Excludes 1

transitory endocrine and metabolic disorders specific to newborn (P70-P74)

Note

All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.

Official Guidelines for E13.52

FY 2026 ›